Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
USFDA granted 6-month pediatric exclusivity to Lyrica, which helps to Lyrica to extent the patent expiration by additional 6 month. Lyrica received... Read More
What is pediatric exclusivity?
Posted on29 Nov 2018
Comments0
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and may run concurrently with a patent but... Read More
Grünenthal entering into US market with acquisition of US based Averitas Pharma
Grünenthal has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be... Read More
Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
Daiichi Sankyo Company, Limited announced that Daiichi Sankyo and GlaxoSmithKline K.K have agreed to dissolve their joint venture company, Japan Vaccine Co,... Read More
Insight on Strides – SUDA Pharma Strategic Deal
Strides Pharma Science’s wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Pharma acquisition Insight: Hikma Pharmaceuticals to acquire Medlac Pharma
Hikma Wednesday said it had a deal to buy Medlac Pharma Italy Co., a Vietnamese injectables manufacturing company established a decade ago... Read More
Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
Secarna Pharmaceuticals (Secarna), a new breed of biopharmaceutical company, has entered into a co-development agreement with MetP Pharma (MetP), a privately held... Read More
Glenmark’S Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd.... Read More
Pfizer gets US FDA approval for Lorbrena for previously-treated ALK-positive metastatic NSCLC
Posted on06 Nov 2018
Comments0
Pfizer Inc announced that the US Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK)... Read More